Detalhe da pesquisa
1.
Biosimilars approvals by thirteen regulatory authorities: A cross-national comparison.
Regul Toxicol Pharmacol
; 144: 105485, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37659711
2.
Utilisation patterns and clinical impact of the introduction of infliximab-biosimilar in Tuscany, Italy: real world evidence following the recommendation of switching for non-medical reasons.
Clin Exp Rheumatol
; 39(4): 753-762, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-32828145
3.
Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients.
Crit Care
; 24(1): 331, 2020 06 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32527304
4.
Olfactory and gustatory impairments in COVID-19 patients: Role in early diagnosis and interferences by concomitant drugs.
Br J Clin Pharmacol
; 87(5): 2186-2188, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33185930
5.
Lessons learnt from the preclinical discovery and development of ensitrelvir as a COVID-19 therapeutic option.
Expert Opin Drug Discov
; 19(1): 9-20, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-37830361
6.
A Cross-National Comparison of Biosimilars Pricing in Argentina, Australia, Brazil, and Italy.
Ther Innov Regul Sci
; 58(3): 549-556, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38436905
7.
Drug Safety and Relevant Issues in the Real-World.
Pharmaceuticals (Basel)
; 16(12)2023 Dec 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38139815
8.
Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence.
Expert Opin Drug Discov
; 18(3): 231-245, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36649625
9.
Potential missed diagnoses of Crohn's disease in tertiary care: impact on drug utilization and healthcare facilities use.
Eur J Gastroenterol Hepatol
; 35(11): 1263-1269, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37724478
10.
Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis.
Pharmaceuticals (Basel)
; 16(3)2023 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36986565
11.
Assessing disease activity of rheumatoid arthritis patients and drug-utilization patterns of biologic disease-modifying antirheumatic drugs in the Tuscany region, Italy.
Front Pharmacol
; 14: 1244486, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37818193
12.
Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall.
Expert Opin Drug Discov
; 17(6): 531-546, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35361043
13.
An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future.
Expert Opin Drug Discov
; 16(12): 1403-1414, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34304682
14.
Trajectories of Adherence to Biologic Disease-Modifying Anti-Rheumatic Drugs in Tuscan Administrative Databases: The Pathfinder Study.
J Clin Med
; 10(24)2021 Dec 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34945038
15.
Validation of algorithms for selecting rheumatoid arthritis patients in the Tuscan healthcare administrative databases.
Sci Rep
; 11(1): 20314, 2021 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-34645838
16.
The Impact of the COVID-19 "Infodemic" on Drug-Utilization Behaviors: Implications for Pharmacovigilance.
Drug Saf
; 43(8): 699-709, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32572842
17.
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline.
MAbs
; 12(1): 1854149, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33319649
18.
Is There a Risk of Lymphoma Associated With Anti-tumor Necrosis Factor Drugs in Patients With Inflammatory Bowel Disease? A Systematic Review of Observational Studies.
Front Pharmacol
; 10: 247, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30941038
19.
Unresolved gustatory, olfactory and auditory adverse drug reactions to antibiotic drugs: a survey of spontaneous reporting to Eudravigilance.
Expert Opin Drug Saf
; 18(12): 1245-1253, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31580740
20.
Potential Direct Costs of Adverse Drug Events and Possible Cost Savings Achievable by their Prevention in Tuscany, Italy: A Model-Based Analysis.
Drug Saf
; 42(3): 427-444, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30276630